Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to SAS’ Q3 2023 teleconference

SAS will publish the interim report for the third quarter of the fiscal year 2023 on Friday, September 1, 2023, at approximately 08.00 AM CEST. A teleconference and webcast for investors, analysts and media will be held at 10.00 AM CEST.Anko van der Werff, President & CEO and Erno Hildén, Executive Vice President & CFO, will present and comment on the report. The presentation will be held in English.   Access via web link (no advance notification is necessary):  https://ir.financialhearings.com/sas-q3-2023 Registration for participation via telephone: https://conference.

Saab showcases missile system on Oshkosh vehicle at DSEI

The purpose is to demonstrate the possibility to integrate the missile-equipped RBS 70 NG Mobile Firing Unit (MFU) with Saab’s ultra-rugged tactical electronics, low-latency video distribution system and the Barracuda Mobile Camouflage System onto the Joint Light Tactical Vehicle (JLTV). Come to Saab’s stand H7-210 at DSEI to learn more.The aim is to address the growing requirements for mobile air defence and strengthen land users capabilities to meet these current and future challenges. Saab's industry-leading MFU uses the RBS 70 NG missile system with its unjammable laser guided missiles,

Mandatory notification of trade - primary insider

Espen Gundersen, member of the Board and Primary insider in Kid ASA, has on 25 August 2023bought 3.000 shares in Kid ASA at an average price of NOK 84,19 per share. Following this transaction, Mr Gundersen holds 7.000 shares in Kid ASA. Please see further details about the transactions in the attached form.This information is subject to disclosure requirements pursuant to §5-12 of theNorwegian Securities Trading Act.

BioStock: CombiGene’s CEO gives a status update

Jan Nilsson, CEO at CombiGene, visited BioStock’s studio to talk about the company’s second quarter. The discussion also covers the collaboration with Zyneyro and the development of new treatments targeting severe chronic pain conditions. We also learn more about a recent meeting with partner Spark Therapeutics, and Nilsson’s stepping down as CEO. Additionally, the interview introduces the new CEO, Peter Ekolind, and explores Nilsson’s future role at CombiGene.Watch the studio interview with Jan Nilsson at biostock.se: CombiGene's CEO gives a status update 

Mandatory Notification of Trade for Primary Insiders

Zurich, August 25, 2023: Dzeki Mackinovski, Executive Vice President Purchasing and primary insider of Kongsberg Automotive ASA has on 24 August 2023 sold 300.000 shares in the company at an average price of NOK 2,273 per share. Following this transaction, Dzeki Mackinovski now holds 853.850 shares in Kongsberg Automotive ASA. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act.

Oxcia AB (publ) publishes interim report for the second quarter 2023

Oxcia AB (publ) Interim report 1 January- 30 June 2023   Second quarter (April-June 2023) · Operating loss totaled SEK -6 937 299 (-7 068 278) · Loss for the period totaled SEK -6 600 725 (-7 068 278) · Cash flow from operating activities totaled SEK 395 205 (-5 963 346) · Earnings per share before dilution totaled SEK -0,31 (-0,33) · Earnings per share after dilution amounted to SEK -0,31 (-0,33) Period (January-June 2023) · Operating loss totaled SEK -23 503 674 (-12 381 412) · Loss for the period totaled SEK -23 051 192 (-12 381 412) · Cash flow

Ahlstrom has signed an agreement to divest Stenay plant to Accursia Capital

AHLSTROM OYJ PRESS RELEASE AUGUST 25, 2023 AT 11:00 EEST Ahlstrom has entered into an agreement to divest its Stenay plant in France to Accursia Capital, following the announcement of Accursia Capital’s binding offer in July. The divestment was confirmed after receiving endorsement from the site’s employee representatives. The transaction is expected to be completed by the end of September. Accursia Capital aims to develop the Stenay plant in order to guarantee its long-term future and, consequently, secure the jobs of its employees. "We are delighted to announce this positive

NYAB Plc's half-yearly report 1 January-30 June 2023: Strong growth and development despite macroeconomic headwinds

NYAB PlcCOMPANY ANNOUNCEMENT25 August 2023 at 10:05NYAB Plc’s half-yearly report 1 January–30 June 2023: Strong growth and development despite macroeconomic headwinds  April-June in brief                                     · Revenue grew 17.2%, amounting to EUR 65.3 (55.7) million · EBITDA was EUR 5.4 (3.5) million, amounting to 8.3% (6.3%) of revenue · Operating profit (EBIT) was EUR 4.0 (2.2) million, amounting to 6.2% (3.9%) of revenue · Free cash flow was EUR 8.4 (-12.8) million · Net debt/EBITDA was 0.19 · Order backlog amounted to EUR 252.0 million (EUR 305.

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 125 - 25 AUGUST 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 112/23 and 113/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

RLS GLOBAL AB (publ) PUBLISHES INTERIM REPORT FOR THE PERIOD APRIL–JUNE 2023

RLS Global AB (publ) (“RLS”) or the “Company”) today publishes the Company’s interim report for the second quarter 2023.APRIL 1st – JUNE 30th (Previous year in brackets) · Net sales amounted to TSEK 223 (TSEK 397) · Earnings before interest and taxes (EBIT) amounted to MSEK -7,5 (MSEK 5,8) · Earnings per share before dilution at SEK -0,09 (SEK 0,09) · Cash flow from operating activities amounted to TSEK -6 904 (TSEK -5 929) · Liquid assets at the end of the period MSEK 4,6 ( MSEK 5,8) · Equity ratio was 71 % (43 %)   JANUARY 1st – JUNE 30th (Previous year in

NIB delivers a strong financial result with a record-high mandate fulfilment

During the first six months of 2023, the Nordic Investment Bank (NIB) signed a total of EUR 1,242 million in new lending and disbursed EUR 1,670 million, compared to EUR 2,203 million and EUR 2,142 million respectively in the same period in 2022. The high demand for NIB lending has allowed the Bank to prioritise high impact projects. During the first half of 2023, new loans were signed to build new wind power capacity and strengthen the electricity distribution networks in the region, for example. In his commentary on the financial results, NIB President and CEO André Küüsvek

Finnair starts direct flights between Rovaniemi and Tromsø

Finnair is improving travel connections in the Arctic region by launching direct flights between Rovaniemi, Finland, and Tromsø, Norway, starting in December.  "The Arctic nature and high-quality travel experiences appeal to travellers from various parts of the world, such as Asia and Central Europe," says Antti Tolvanen, SVP Network & Revenue Management at Finnair. "With this new connection, visitors to the Arctic region can conveniently combine both Lapland and Northern Norway in one trip."  There will be two weekly flights between Tromsø and Rovaniemi that are operated by 68-seater

Movinn H1 2023 - Interim Report: +21% topline growth, with weaker demand in secondary domestic markets resulting in disappointing bottom-line performance.

Growth remain substantial and Movinn Sverige is close to B/E point. Demand in Q2 did not pick up fast enough to offset a weak Q1 resulting in disappointing bottom line performance. Consequently, we are facing a downward adjustment to our full year guidance.Company Announcement nr. 30 - 202325 August 2022 09.00 CET. This company announcement contains inside information.  Copenhagen, Denmark - The Interim Report covers results from the first half of the year (H1) of the year (1 January - 30 June 2022), as approved by Executive Management and the Board of Directors.  In H1 Movinn has

ANTON ALSÖ JOINS MANDATUM AS CREDIT PORTFOLIO MANAGER

Anton Alsö (47) has been appointed to Mandatum's portfolio management organization as Senior Portfolio Manager for credit investments as of October 1, 2023. Alsö has previously worked, for example, in If's credit investment portfolio management team for 12 years focusing on high yield credit. He is joining Mandatum from Arctic Securities Stockholm's debt capital market unit. Alsö will be based in Mandatum’s Stockholm office. "I am extremely pleased to have Anton Alsö joining our portfolio management team. He is one of the most experienced credit portfolio managers in the Nordic

Strong growth for cool roof paint containing Quartzene[®] – French customer places regular orders

Svenska Aerogel is once again sending an order – this time for 720 kg of Quartzene[®] – to its returning French customer Renovcoat. Renovcoat sells cool roof paint containing Quartzene[®] in the French and African markets. The company is now gaining market share in France, and the number of installed square meters is steadily increasing.Svenska Aerogel now delivers Quartzene® to Renovcoat on a regular basis. Renovcoat uses the material for reflection and insulation in its cool roof paint, as Quartzene® offers excellent insulating properties and a high SRI (solar reflectance index).

BioStock: Progress for Stayble Therapeutics in the second quarter

The second quarter was an intense period with several important achievements for the Gothenburg-based pharmaceutical company Stayble Therapeutics. After a successful capital raise, the company can run the two ongoing studies with STA363 at the desired pace. According to the plan, the phase IIb study in degenerative disc disease will be completed in the second half of 2023. The company also looks forward to treating the first patient in the phase Ib study in herniated discs.Read the full article at biostock.se: https://www.biostock.se/en/2023/08/progress-for-stayble-therapeutics-in-the-

Dicot's clinical phase 1 study starts today

Press release: Uppsala, August 25, 2023. Today is the formal start of Dicot's clinical phase 1 study with the drug candidate LIB-01 as the first screening visit is being performed. The study is a placebo-controlled trial with the primary objective to evaluate the safety profile in humans.Last week, Dicot received approval from the relevant authorities to start a clinical phase 1 trial. Dicot's partner CTC, which will conduct the study, began recruiting participants immediately. Since all other preparations were completed, the study can start today, just over a week after the approval. It

Clean Industry Solutions Holding Europe AB: Quarterly Report April-June 2023

Q2 from 01.04.2023 to 30.06.2023 (01.04.2022 to 30.06.2022), 01-06 from 01.01.2023 to 30.06.2023 (01.01.2022 to 30.06.2022), FY from 01.01.2022 to 31.12.2022 Significant events during the reporting period · Industrial Solar Awarded 196k€ for R&D Project SUSHEAT · Industrial Solar Wins GIZ Tender for Renewable Process Heat · Bulletin from Clean Industry Solutions Holding Europe AB Annual General Meeting 2023 · Renewed Update on Project with KEBE S.A. in Greece · Industrial Solar to install Photovoltaic System for Wössner GmbH · Clean Industry Solutions Holding

Heliospectra (publ) Publish the Half-Year Report for January to June 2023

(GOTHENBURG, Sweden, Aug 25, 2023, at 08:35 CEST)– Heliospectra AB (publ), a leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents its Half-Year Report for January to June 2023.Full report is enclosed to this press release and is also uploaded at https://heliospectra.com/investor-relations/financial-reports-documents/reports/. SUMMARY OF REPORT Sales and financial performance April – June 2023 · Order intake during the period amounted to SEK 9,503 (5,346) thousand. · Net sales during the period amounted to SEK 10,094 (3,349)

Ellos Group AB (publ) interim report January - June 2023

Press release, Borås, 25 August 2023The interim report for Ellos Group AB (publ) is published today. THE SECOND QUARTER 2023• Net sales decreased by 6.6 % to SEK 802.1 (858.4) million. Organically, net sales decreased by 2.2 %.• The gross margin increased to 53.6 (51.5) %.• Adjusted EBITA amounted to SEK 41.3 (8.4) million. The adjusted EBITA margin* stood at 5.1 (1.0) %.• The operating profit/loss amounted to SEK 13.8 (-1.7) million. The operating margin was 1.7 (-0.2) %.• Cash flow from operating activities amounted to SEK 25.8 (16.8) million.• Inventories amounted to SEK

Cereno Scientific publishes the interim report for Q2 2023 ( April 1 – June 30)

The Board and Chief Executive Officer of Cereno Scientific AB here present the interim report for Q2 2023 ( April 1 – June 30).Summary of the interim report for Q2 2023 ( April 1 – June 30) Cereno Scientific Group · Result after financial items was SEK 10,686,053 (-6,518,033) · Earnings per share was SEK -0.05 (-0.06) before dilution and SEK -0.04 (-0.04) after dilution · The equity/assets ratio was 95.4% (93.2%) · Cash and bank balance was SEK 85,291,722 SEK (63,257,948) Parent company · Result after financial items was SEK -10,697,871 (-6,747,978) · Earnings

H1 2023 Interim Report - Donkey Republic realizes positive EBITDA and 118% revenue growth in H1-2023. EBIT guidance for 2023 is adjusted upwards.

Financial report for the period 1 January 2023 - 30 June 2023*Contains inside information*Company Announcement No. 21 2023Financial overview Doubling the revenue and improving the contribution margin to over 50% while keeping the fixed cost on a stable level, enabled Donkey Republic to record a positive EBITDA for the first time in its history. With a profitable operation in place and further bikes available to deploy, the company is in a good position to continue its growth path and achieve its full year guidance. The capital raise that was concluded in July furthermore provides

Pharmacolog publishes interim report January - June 2023

Pharmacolog i Uppsala AB (publ) announces today that the interim report for the period January - June 2023 has been published.The annual report is attached as a PDF and is available on the company's website:https://pharmacolog.com/investor-relations-2/financial-reports/ (Swedish only). Second quarter April 1 – June 30 2023 · Consolidated net sales for the second quarter amounted to 1 279 (3 221) KSEK. · Operating result for the quarter amounted to -5 589 (-4 783) KSEK. · Net earnings per share before and after dilution for the quarter were -0,29 (-0,31) SEK. First six

Erik Jivmark appointed as new CEO of Sleep Cycle AB (publ)

In agreement with the company’s board, Carl Johan Hederoth steps down as CEO of Sleep Cycle AB (publ), the global leader in the development of AI-based sleep analysis. The board has today decided to appoint Erik Jivmark as the new CEO of Sleep Cycle as of 1 November 2023.Erik Jivmark has extensive international experience from leading positions within digital products and services. Erik comes from the role as CEO of Volvo Car Mobility AB and leading the Volvo Cars Stockholm Tech Hub. Before that Erik was the Global Director of Digital at Volvo Cars AB based in both Sweden and the U.S. He

There are no items matching the current filter
There are no more items matching the current filter
Back to top